Clinical Trials Browser

Phase 2/3 × INDUSTRY × Naloxone × Clear all

NCT02321397 2016-11-04

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Phase 2/3 Completed

Bronchiolitis Obliterans Syndrome